Progyny (NASDAQ:PGNY) Stock Bumped Down to “Buy” by Wall Street Zen

Wall Street Zen downgraded shares of Progyny (NASDAQ:PGNY) from a strong-buy rating to a buy rating in a report released on Saturday morning,Wall Street Zen reports.

PGNY has been the topic of several other reports. Truist Financial boosted their price objective on shares of Progyny from $33.00 to $36.00 and gave the stock a “buy” rating in a research report on Thursday, August 13th. Citizens Jmp raised their price target on Progyny from $31.00 to $33.00 and gave the stock a “market outperform” rating in a research report on Tuesday, September 8th. KeyCorp boosted their price target on Progyny from $30.00 to $35.00 and gave the stock an “overweight” rating in a report on Monday, July 13th. Citigroup restated an “outperform” rating on shares of Progyny in a research report on Tuesday, September 8th. Finally, Zacks Research lowered shares of Progyny from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 19th. Nine equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $34.36.

Progyny Stock Performance

PGNY opened at $29.19 on Friday. The business’s 50-day simple moving average is $26.88 and its 200-day simple moving average is $24.43. The company has a market cap of $2.24 billion, a P/E ratio of 31.73, a PEG ratio of 2.01 and a beta of 1.02. Progyny has a one year low of $16.10 and a one year high of $33.06.

Progyny (NASDAQ:PGNY) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.55 EPS for the quarter, topping the consensus estimate of $0.33 by $0.22. Progyny had a return on equity of 15.98% and a net margin of 6.00%. The company had revenue of $350.51 million for the quarter, compared to analyst estimates of $349.05 million. During the same quarter in the previous year, the company posted $0.19 earnings per share. The firm’s revenue was up 5.3% compared to the same quarter last year. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. As a group, analysts predict that Progyny will post 1.25 earnings per share for the current fiscal year.

Insider Transactions at Progyny

In other news, EVP Allison Swartz sold 3,903 shares of the stock in a transaction on Wednesday, September 23rd. The stock was sold at an average price of $26.10, for a total value of $101,868.30. Following the completion of the transaction, the executive vice president owned 75,816 shares of the company’s stock, valued at approximately $1,978,797.60. This represents a 4.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Melissa Cummings sold 1,879 shares of the stock in a transaction that occurred on Wednesday, October 14th. The shares were sold at an average price of $28.00, for a total transaction of $52,612.00. Following the completion of the transaction, the chief operating officer owned 66,496 shares of the company’s stock, valued at $1,861,888. This trade represents a 2.75% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 17,282 shares of company stock worth $475,790. Company insiders own 9.90% of the company’s stock.

Institutional Investors Weigh In On Progyny

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Oregon Public Employees Retirement Fund grew its holdings in Progyny by 4.2% during the third quarter. Oregon Public Employees Retirement Fund now owns 17,254 shares of the company’s stock valued at $435,000 after purchasing an additional 700 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in Progyny in the third quarter valued at about $278,000. Summit Global Investments bought a new stake in Progyny in the third quarter valued at $1,105,000. State of Wyoming boosted its holdings in shares of Progyny by 3.5% in the 3rd quarter. State of Wyoming now owns 29,806 shares of the company’s stock worth $751,000 after acquiring an additional 1,015 shares in the last quarter. Finally, Sterling Capital Management LLC increased its stake in shares of Progyny by 17.0% in the third quarter. Sterling Capital Management LLC now owns 15,068 shares of the company’s stock valued at $380,000 after buying an additional 2,191 shares in the last quarter. 94.93% of the stock is currently owned by institutional investors.

About Progyny

Progyny, Inc is a benefits-management company focused on fertility and family-building care. The company works with employers to provide comprehensive benefits that help members access fertility treatments and related services through a network of specialized providers.

Its offerings include coverage and support for services such as in vitro fertilization, fertility testing, egg and sperm freezing, donor services, gestational surrogacy, and adoption. Progyny also provides pharmacy benefits through Progyny Rx, as well as personalized guidance intended to help members navigate treatment options, providers, and the broader family-building process.

Progyny primarily serves self-insured employers and their employees in the United States.